Calamos Advisors LLC Acquires 651,000 Shares of Kenvue Inc. $KVUE

Calamos Advisors LLC raised its stake in Kenvue Inc. (NYSE:KVUE) by 24.1% during the first quarter, Holdings Channel reports. The fund owned 3,351,000 shares of the company’s stock after buying an additional 651,000 shares during the period. Calamos Advisors LLC’s holdings in Kenvue were worth $57,771,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently added to or reduced their stakes in KVUE. Arrowstreet Capital Limited Partnership purchased a new stake in shares of Kenvue during the second quarter worth $6,528,000. Jump Financial LLC boosted its stake in Kenvue by 210.6% in the second quarter. Jump Financial LLC now owns 54,823 shares of the company’s stock worth $1,147,000 after buying an additional 37,170 shares in the last quarter. AXA S.A. boosted its position in Kenvue by 21.1% during the 2nd quarter. AXA S.A. now owns 48,892 shares of the company’s stock valued at $1,023,000 after buying an additional 8,524 shares during the period. NewEdge Advisors LLC grew its stake in shares of Kenvue by 219.1% in the second quarter. NewEdge Advisors LLC now owns 97,481 shares of the company’s stock worth $2,040,000 after purchasing an additional 66,930 shares during the last quarter. Finally, The Manufacturers Life Insurance Company grew its position in shares of Kenvue by 0.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 1,873,705 shares of the company’s stock worth $39,217,000 after buying an additional 10,885 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Insider Activity at Kenvue

In related news, General Counsel Matthew Orlando sold 38,491 shares of the company’s stock in a transaction on Friday, May 8th. The stock was sold at an average price of $17.66, for a total transaction of $679,751.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 1.59% of the company’s stock.

Kenvue Stock Performance

Kenvue stock opened at $19.24 on Tuesday. The firm has a market capitalization of $36.95 billion, a P/E ratio of 22.64, a price-to-earnings-growth ratio of 1.48 and a beta of 0.47. The company’s 50-day moving average is $18.10 and its 200 day moving average is $17.81. Kenvue Inc. has a 1-year low of $14.02 and a 1-year high of $22.87. The company has a debt-to-equity ratio of 0.67, a current ratio of 0.98 and a quick ratio of 0.70.

Kenvue (NYSE:KVUE) last released its earnings results on Thursday, May 7th. The company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.05. Kenvue had a return on equity of 20.81% and a net margin of 10.61%.The business had revenue of $3.91 billion for the quarter, compared to analyst estimates of $3.84 billion. During the same quarter last year, the firm posted $0.24 earnings per share. The business’s revenue was up 4.5% compared to the same quarter last year. Research analysts forecast that Kenvue Inc. will post 1.16 EPS for the current year.

Kenvue Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, May 27th. Investors of record on Wednesday, May 13th were paid a $0.2075 dividend. The ex-dividend date of this dividend was Wednesday, May 13th. This represents a $0.83 dividend on an annualized basis and a yield of 4.3%. Kenvue’s payout ratio is 97.65%.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. Barclays reduced their target price on shares of Kenvue from $19.00 to $18.00 and set an “equal weight” rating on the stock in a research report on Tuesday, April 14th. Zacks Research cut shares of Kenvue from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 7th. Citigroup reduced their price objective on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a research note on Wednesday, April 15th. UBS Group cut their target price on Kenvue from $19.00 to $18.00 and set a “neutral” rating for the company in a research report on Tuesday, April 7th. Finally, Wall Street Zen raised shares of Kenvue to a “buy” rating in a research note on Sunday. Three analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $19.33.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.